Skip to Main Content

Paper Details

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.
Pigment Cell Melanoma Res
20
2015

Datasets

Release 1.2